RegeneRx Biopharma receives patent in Korea
Singapore, Jan. 23 -- US based RegeneRx Biopharmaceuticals, a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported that the Korean Intellectual Property Office has issued a new patent to the Henry Ford Health System (HFHS) for a Thymosin beta 4 (T?4) composition for reducing diabetic-induced vascular dysfunction. T?4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-352, a first-in-class injectable formulation designed for systemic administration for tissue regeneration and repair.
RegeneRx in-licensed the intellectual property relating to the use of T?4 for this indication from HFHS in Detroit, MI based on work performed by Dr. Michael Chopp and his c...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.